logo
FDRHPO promotes colorectal cancer screening via regional partnerships

FDRHPO promotes colorectal cancer screening via regional partnerships

Yahoo10-03-2025

FORT DRUM, N.Y. (WWTI) – Fort Drum Regional Health Planning Organization is nearing the successful completion of an 18-month grant from Exact Sciences to help provide colorectal cancer screenings.
Exact Sciences is a leading provider of cancer screening and diagnostic tests, to improve colorectal cancer screening rates and make healthcare more accessible throughout the north country region.
James Van Der Beek of 'Dawson's Creek' shares cancer diagnosis
The grant promoted colorectal cancer screenings among marginalized elderly, low-income, and disabled populations throughout New York's rural Jefferson, Lewis, and St. Lawrence counties by supporting the region's primary care practices in identifying and outreaching eligible patients and promoting awareness of colorectal cancer screening through a multimedia campaign.
The grant was made possible through Exact Sciences' Funding Opportunities for Colorectal Cancer Screening Uptake Strategies Program, which provides funding to community organizations, health foundations, public health organizations, and advocacy groups working to increase access to colorectal cancer screening. Exact Sciences developed Cologuard, the first and only FDA-approved, noninvasive, multi-target, stool-based DNA screening test that people can use at home.
Colorectal cancer is one of the most preventable cancers, yet approximately 60 million average-risk Americans remain unscreened. Awareness and access are critical to increasing screening participation, and Exact Sciences is honored to support these organizations that are driving screening uptake and addressing inequities within their communities.
Paul Limburg, Chief Medical Officer of screening, at Exact Sciences
FDRHPO utilized data provided by Medicare and Managed Medicaid insurers to identify patients in the region who were due for colorectal cancer screening and worked with 11 primary care partners to outreach patients and track screening completion.
FDRHPO Communication's Committee also collaborated with other primary healthcare, inpatient, behavioral healthcare, and social care providers in the region to develop a marketing campaign. The campaign included messaging that screening generally starts at age 45; both men and women need to be screened; when caught early enough, roughly 90 percent of those diagnosed will successfully treat it; and that individuals should talk to their healthcare provider to determine which screening option is best for them.
The primary project goal was to complete 1,250 colorectal cancer screenings among the target population; at the time of writing, FDRHPO and its partners have exceeded the goal, having completed nearly 1,500 screenings.
FDRHPO houses a collection of educational graphics about colorectal cancer screening on its website at https://www.fdrhpo.org/colocancerresources; providers and the general public are invited to utilize and share these at no cost.
In addition to the colorectal cancer screening grant, FDRHPO and NCI collaborate with partners to impact a host of regional health behaviors and outcomes. Examples of collaborative regional initiatives include:
A separately funded project to promote breast cancer screening through the use of mobile mammography equipment in community 'hotspot' locations;
A three-year initiative to place community health workers in primary care practices to promote a range of preventive and chronic care among North Country patients;
Financial and technical support to primary care and behavioral care partners to provide transitional and chronic care management services to Medicaid-insured populations, for whom such services are not otherwise available. Recent analysis indicated that transitional care management services for Medicaid-insured patients in the region are linked to a 40% reduction in 90-day post-discharge healthcare costs, 14% lower inpatient readmission rates, and a 36% increase in documentation of social care needs;
Regional media campaigns, such as 'Call Us First' which encourages people to contact their primary care team for minor acute needs, and 'Healthy Habits' which encourages people to re-engage in primary and preventive care, notably annual wellness visits, recommended screenings, dental/oral care, and immunizations;
Adoption of a standardized screening tool that clinical and behavioral providers use to identify social needs among those they serve, document identified needs and make 'closed loop' referrals to relevant services;
A qualitative and quantitative research project to uncover perspectives and trends about accessing and experiencing primary care among elderly, low-income, and/or disabled regional residents, with recommended action steps for primary care, behavioral healthcare, and health insurance providers;
Provision of trainings to clinical, behavioral, and social care staff to improve understanding of, relationships with, and strategies to impact their patient populations;
Implementation of multiple value-based payment arrangements, whereby groups of clinical and behavioral partners collaboratively seek to steward the healthcare costs and improve quality measure compliance among more than 26,000 patients in the region; and
Financial awards to more than a dozen clinical, behavioral, and social care organizations since 2021 to pilot or conduct 'promising practice' interventions, including projects to reduce fall risk among elderly or disabled individuals; increase management of high blood pressure and diabetes; use telemedicine and remote patient monitoring to treat behavioral and substance use needs and better manage patients with chronic conditions; deploy community health workers to connect people to clinical and social resources; and promote transitional and chronic care management, childhood immunizations, and well-child visits.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

Yahoo

time28 minutes ago

  • Yahoo

Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD). In the first week of June, Mesoblast held a Type B meeting with FDA under its Regenerative Medicines Advanced Therapy (RMAT) designation for REVASCOR to discuss components of a potential filing for a Biologics License Application (BLA). There was general alignment on items regarding chemistry, manufacturing & controls (CMC), potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval. The Company will await the final minutes from FDA in order to provide detailed feedback and timelines for potential filing. In early July, Mesoblast has an upcoming meeting with FDA to discuss a pivotal trial of Ryoncil® in adults with SR-aGvHD. This trial will be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN), the objective being to extend the product's label from children to adults with SR-aGvHD. Ryoncil® is the first and only mesenchymal stromal cell product approved by the FDA for any indication. Ryoncil® became commercially available for purchase in the United States on March 28, 2025, within one quarter of receiving FDA approval to treat children with SR-aGvHD. More than 20 transplant centers will have been onboarded by the end of the quarter, exceeding the company's expectations at product launch. Mesoblast has continued to expand coverage for Ryoncil® to over 220 million US lives insured by commercial and government payers. To date, 37 of the 51 States provide fee-for-service Medicaid coverage for Ryoncil® through Orphan Drug Lists or medical exception / prior authorization (PA) process. The remainder will come online July 1, 2025, with mandatory coverage for all 24 million lives. 'We are very pleased with the momentum of interactions with FDA on both our cardiac and GvHD programs,' said Mesoblast Chief Executive Dr. Silviu Itescu. 'We are also encouraged by the strength of the of the Ryoncil® commercial launch, the rate of hospital onboarding, physician adoption, and payor coverage exceeding our expectations in the ten weeks since commercial launch. We will be providing an update on sales of Ryoncil® in our quarterly activities report at the end of next month.' About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast's RYONCIL® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets. About Mesoblast manufacturing: The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see LinkedIn: Mesoblast Limited and X: @Mesoblast Forward-Looking StatementsThis press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast's preclinical and clinical studies, and Mesoblast's research and development programs; Mesoblast's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast's ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast's RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast's product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast's ability to enter into and maintain established strategic collaborations; Mesoblast's ability to establish and maintain intellectual property on its product candidates and Mesoblast's ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast's expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast's financial performance; developments relating to Mesoblast's competitors and industry; and the pricing and reimbursement of Mesoblast's product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact:Paul Hughes T: +61 3 9639 6036 Allison Worldwide Emma Neal T: +1 603 545 4843 E: BlueDot Media Steve Dabkowski T: +61 419 880 486 E: steve@

RFK Jr.'s newest CDC vaccine panel includes critics of COVID shots, lockdowns
RFK Jr.'s newest CDC vaccine panel includes critics of COVID shots, lockdowns

Yahoo

time36 minutes ago

  • Yahoo

RFK Jr.'s newest CDC vaccine panel includes critics of COVID shots, lockdowns

The Brief U.S. Health Secretary Robert F. Kennedy Jr. has replaced the government's vaccine advisory panel with eight new appointees. The new members include vocal critics of COVID-19 vaccines and pandemic lockdowns, such as Dr. Robert Malone and Dr. Martin Kulldorff. Public health groups have raised concerns that Kennedy's changes could undermine long-standing vaccination policies. NEW YORK - U.S. Health Secretary Robert F. Kennedy Jr. has named eight new vaccine policy advisers to replace the panel that he abruptly dismissed earlier this week. His selections include a scientist who researched mRNA vaccine technology and transformed into a conservative darling for his criticisms of COVID-19 vaccines, and a leading critic of pandemic-era lockdowns. RELATED: RFK Jr. ousts entire CDC vaccine panel Kennedy made the announcement in a social media post on Wednesday. The backstory Kennedy's decision to "retire" the previous 17-member panel was widely decried by doctors' groups and public health organizations, who feared the advisers would be replaced by a group aligned with Kennedy's desire to reassess — and possibly end — longstanding vaccination recommendations. Dig deeper The new appointees to the Advisory Committee on Immunization Practices include Dr. Robert Malone, the former mRNA researcher who emerged as a close adviser to Kennedy during the measles outbreak. Malone, who runs a wellness institute and a popular blog, rose to popularity during the COVID-19 pandemic as he relayed conspiracy theories around the outbreak and the vaccines that followed. He has appeared on podcasts and other conservative news outlets where he's promoted unproven and alternative treatments for measles and COVID-19. He has claimed that millions of Americans were hypnotized into taking the COVID-19 shots. He's even suggested that those vaccines cause a form of AIDS. He's downplayed deaths related to one of the largest measles outbreaks in the U.S. in years. Other appointees include Dr. Martin Kulldorff, a biostatistician and epidemiologist who was a co-author of the Great Barrington Declaration, an October 2020 letter maintaining that pandemic shutdowns were causing irreparable harm. Dr. Cody Meissner, a former ACIP member, also was named. Big picture view The committee, created in 1964, makes recommendations to the director of the Centers for Disease Control and Prevention. CDC directors almost always approve those recommendations on how Food and Drug Administration-cleared vaccines should be used. The CDC's final recommendations are widely heeded by doctors and determine the scope of vaccination programs. The Source The Associated Press contributed to this report. The information in this story comes from a social media announcement made by U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday, in which he introduced eight new members to the federal vaccine advisory panel. This story was reported from Los Angeles.

OHA uncovers latest report highlighting issues at Oregon's psychiatric hospital
OHA uncovers latest report highlighting issues at Oregon's psychiatric hospital

Yahoo

time37 minutes ago

  • Yahoo

OHA uncovers latest report highlighting issues at Oregon's psychiatric hospital

PORTLAND, Ore. () — Oregon State Hospital has less than two months to prove it is now in compliance with federal standards and maintain its Medicare agreement. The state's public health leaders have uncovered a survey they conducted at the Salem behavioral health facility on Apr. 29. According to the , investigators found OSH 'was not in substantial compliance' with several regulations related to its governing body, patient rights and special provisions for psychiatric hospitals. 'Deeply private': Oregon AG challenges potential sale of 23andMe users' personal data The survey came after a patient's death in March, which led to the Joint Commission conducting its own report and . The Oregon Health Authority's newly released investigation shows that several staff members told surveyors that executive leadership 'largely ignored and dismissed' warnings and complaints about safety at the hospital. OHA's statement of deficiencies also alleged employees were 'coached' on what to say during the probe from officials. Any corrective actions that were established in response to the survey were soon discontinued, the document shows. 'This report is a clarion call for the need for the immediate changes being implemented now that will have impact to assure that patients at OSH are safe and receiving the care they need and deserve,' OHA Deputy Director Dave Baden, who is the hospital's active superintendent as of April 11, said in a statement. 'Sustained and ongoing cultural changes at the hospital will take time. We need to improve our processes in support of not only patients in seclusion or high-risk patients, but every patient at OSH.' The public health agency's report also includes a letter from the Centers for Medicare & Medicaid Services. According to CMS' health insurance specialist, the Oregon psychiatric facility's Medicare agreement is currently set to terminate on Aug. 4. This means that Medicare won't cover services for patients admitted on or after that date. Patients admitted ahead of the deadline could still receive payment for another 30 days. Port of Portland OKs lease for mass timber facility to boost jobs, housing Federal officials said the termination would only be averted if the facility created a plan of correction, which was due on June 2. According to Baden, OSH has already paused telework for patient-facing staff and required leadership to regularly visit units in order to help employees serve the hospital. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store